ArticleNeurology2014
Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS.
Article in Neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03561402 (Association of Possible Biomarkers With Disease Activity in Patients Treated With Teriflunomide), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Association of Possible Biomarkers With Disease Activity in Patients Treated With Teriflunomide (Aubagio)
Who cites it
11 citing papers in PubMed, 28 citations in OpenAlex.
- Proteomic profiling in multiple sclerosis clinical courses reveals potential biomarkers of neurodegeneration.PloS one · 2014Trial
- The Plasticity of Immune Cell Response Complicates Dissecting the Underlying Pathology of Multiple Sclerosis.Journal of immunology research · 2024Review
- Discovery of grey matter lesion-related immune genes for diagnostic prediction in multiple sclerosis.PeerJ · 2023Article
- T-cell surveillance of the human brain in health and multiple sclerosis.Seminars in immunopathology · 2022Review
- The Putative Association of TOB1-AS1 Long Non-coding RNA with Immune Tolerance: A Study on Multiple Sclerosis Patients.Neuromolecular medicine · 2020Article
- Enhanced TLR2 responses in multiple sclerosis.Clinical and experimental immunology · 2018Article
- Different interleukin-17-secreting Toll-like receptorImmunology · 2018Article
- Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients.BMC neurology · 2017Article
- Human CD4(+) T-Cells: A Role for Low-Affinity Fc Receptors.Frontiers in immunology · 2016Review
- Granzyme B-inhibitor serpina3n induces neuroprotection in vitro and in vivo.Journal of neuroinflammation · 2015Article
- Increased CXCL10 expression in MS MSCs and monocytes is unaffected by AHSCT.Annals of clinical and translational neurology · 2014Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOur objective was to determine whether altered naive CD4 T-cell biology contributes to development of disease progression in secondary progressive multiple sclerosis (SPMS).
methodsWe compared the naive CD4 T-cell gene expression profiles of 19 patients with SPMS and 14 healthy controls (HCs) using a whole-genome microarray approach. We analyzed surface protein expression of critical genes by flow cytometry after T-cell receptor (TCR) stimulation of naive CD4 T cells isolated from HCs and patients with SPMS.
resultsHierarchical clustering segregated patients with SPMS into 2 subgroups: SP-1, which had a short duration of relapsing-remitting multiple sclerosis (MS), and SP-2, which had a long duration of relapsing-remitting MS. SP-1 patients upregulated numerous immune genes, including genes within TCR and toll-like receptor (TLR) signaling pathways. SP-2 patients showed immune gene downregulation in comparison with HCs. We identified an SP-1-specific transcriptional signature of 3 genes (TLR4, TLR2, and chemokine receptor 1), and these genes had higher surface protein expression in SP-1 than in SP-2. After TCR stimulation for 48 hours, only SP-1 showed a progressive linear increase in TLR2 and TLR4 protein expression.
conclusionsDifferences in naive CD4 T-cell biology, notably of TCR and TLR signaling pathways, identified patients with MS with more rapid conversion to secondary progression, a critical determinant of long-term disability in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.